{"DataElement":{"publicId":"3191479","version":"1","preferredName":"Anticoagulant Agent At Discharge Prescription Type","preferredDefinition":"Types of prescribed anticoagulant medications at discharge.","longName":"ACGLNT_DSCHRG_TYP","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3191469","version":"1","preferredName":"Anticoagulant Agent At Discharge Prescription","preferredDefinition":"Prescrbed anticoagulants at discharge.","longName":"ACGLNT_PRSC_DSCHRG","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2199736","version":"1","preferredName":"Anticoagulant Agent","preferredDefinition":"Agents that prevent blood clotting. Naturally occurring agents in the blood are included only when they are used as drugs.","longName":"Anticoagulant Agent","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Anticoagulant Agent","conceptCode":"C263","definition":"Any agent capable of preventing blood clot formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF9DAC66-6126-24E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3191457","version":"1","preferredName":"At Discharge Prescription","preferredDefinition":"Used to indicate position, location, or state (American Heritage Dictionary):In healthcare, discharge represents the end point of an inpatient hospital contact which consists of one or several days of care. (from Wikipedia):A doctor's order for medicine or another intervention.","longName":"C25427:C25166:C28180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"At","conceptCode":"C25427","definition":"Used to indicate position, location, or state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Patient Discharge","conceptCode":"C25166","definition":"The release of a patient from a course of care.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prescription","conceptCode":"C28180","definition":"A verbal or written order given by an authorized person instructing a patient to obtain and use a medical device, prescription or undergo a procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C038308-DD30-FB58-E040-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"ONEDATA","dateModified":"2011-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C03939E-9817-2D26-E040-BB89AD4356ED","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"TSESU","dateModified":"2018-05-25","changeDescription":"5/25/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3191441","version":"1","preferredName":"Anticoagulant Agent Type","preferredDefinition":"Type of agents that prevent blood clotting.","longName":"ACGLNT_TYP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5A32C-4F9F-EC58-E040-BB89AD437BD3","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Fondaparinux (Arixtra)","valueDescription":"Fondaparinux","ValueMeaning":{"publicId":"3191442","version":"1","preferredName":"Fondaparinux","longName":"3191442","preferredDefinition":"A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fondaparinux","conceptCode":"C73142","definition":"A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5A32C-4FAB-EC58-E040-BB89AD437BD3","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5A32C-4FC4-EC58-E040-BB89AD437BD3","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Warfarin (Coumadin)","valueDescription":"Warfarin","ValueMeaning":{"publicId":"3191443","version":"1","preferredName":"Warfarin","longName":"3191443","preferredDefinition":"A synthetic anticoagulant. Warfarin appears to inhibit the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Warfarin","conceptCode":"C945","definition":"A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5A32C-4FD0-EC58-E040-BB89AD437BD3","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5A32C-4FE9-EC58-E040-BB89AD437BD3","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Full dose LMW heparin (Enoxaparin, Others)","valueDescription":"Full Dose Low Molecular Weight Heparin","ValueMeaning":{"publicId":"3191444","version":"1","preferredName":"Full Dose Low Molecular Weight Heparin","longName":"3191444","preferredDefinition":"Containing as much or as many as is possible or normal.: The amount of medicine taken, or radiation given, at one time.: Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Full","conceptCode":"C25517","definition":"Containing as much or as many as is possible or normal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Low Molecular Weight Heparin","conceptCode":"C2578","definition":"Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5A32C-4FF7-EC58-E040-BB89AD437BD3","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5A32C-5010-EC58-E040-BB89AD437BD3","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Unfractionated heparin IV","valueDescription":"No Fractions Intravenous Heparin","ValueMeaning":{"publicId":"3191445","version":"1","preferredName":"No Fractions Intravenous Heparin","longName":"3191445","preferredDefinition":"The non-affirmative response to a question.: Fraction; a small part or item forming a piece of a whole.: (in-tra-VEE-nus) IV. Within a blood vessel.: A glycosaminoglycan anticoagulant that binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Fraction","conceptCode":"C25514","definition":"A part, a fragment of a whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Intravenous","conceptCode":"C13346","definition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Heparin","conceptCode":"C539","definition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5A32C-501F-EC58-E040-BB89AD437BD3","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BF5A32C-5038-EC58-E040-BB89AD437BD3","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3191440","version":"1","preferredName":"Anticoagulant Agent Type","preferredDefinition":"Agents that prevent blood clotting. Naturally occurring agents in the blood are included only when they are used as drugs.:Type; a subdivision of a particular kind of thing.","longName":"C263:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anticoagulant Agent","conceptCode":"C263","definition":"Any agent capable of preventing blood clot formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5A32C-4F7B-EC58-E040-BB89AD437BD3","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"ONEDATA","dateModified":"2011-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BF5A32C-4F8C-EC58-E040-BB89AD437BD3","latestVersionIndicator":"Yes","beginDate":"2011-02-10","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-10","modifiedBy":"SBR","dateModified":"2018-12-20","changeDescription":"5/29/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.\r\n\r\n","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6272292","version":"1","longName":"NINDS","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000330","version":"1","longName":"Treatment/Intervention Data","context":"NCIP"},{"publicId":"3151265","version":"1","longName":"Drugs","context":"NCIP"},{"publicId":"3188342","version":"1","longName":"Antithrombotics and Risk Factor Controlling Medications","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If anticoagulants prescribed,","type":"Preferred Question Text","description":"If anticoagulants prescribed, specify type(s).","url":null,"context":"NCIP"},{"name":"NINDS CDE Project","type":"REFERENCE","description":"NINDS CDE Project","url":"http://www.commondataelements.ninds.nih.gov/","context":"NCIP"}],"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C0453A0-EFA5-7439-E040-BB89AD434BF1","latestVersionIndicator":"Yes","beginDate":"2011-02-11","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-11","modifiedBy":"SBR","dateModified":"2018-12-20","changeDescription":"5/25/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}